Literature DB >> 20710061

Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.

Andrea Krüsi1, M-J Milloy, Thomas Kerr, Ruth Zhang, Silvia Guillemi, Robert Hogg, Julio Montaner, Evan Wood.   

Abstract

BACKGROUND: The effect of ongoing illicit drug use on HIV treatment remains controversial, especially in countries where access to HIV treatment for active injection drug users (IDUs) is limited because of presumed non-adherence. We sought to investigate the influence of drug use patterns on adherence to antiretroviral therapy and virological suppression among IDUs.
METHODS: Using generalized estimating equation logistic regression, we explored the effect of abstinence versus ongoing drug use on adherence and virological suppression using data from a community-recruited cohort of IDUs in Vancouver (BC, Canada).
RESULTS: A total of 381 HIV-positive IDUs were included in this analysis, among whom the median follow-up time was 30 months. In a multivariate model, no relationship was found between abstinence (reference) and active injection (adjusted odds ratio [AOR] 0.88, 95% confidence interval [CI] 0.65-1.17) and non-injection (AOR 0.97, 95% CI 0.67-1.41) drug use with adherence. In subanalyses, ongoing injection drug use was associated with a lower odds of virological suppression in comparison to abstinence (AOR 0.74, 95% CI 0.57-0.97; P=0.026) and both active IDUs and active non-IDUs had lower odds of virological suppression compared with abstinent participants when longer periods of virological suppression were considered.
CONCLUSIONS: Given the absence of a strong relationship between abstinence and ongoing drug use and adherence among HIV-positive IDUs, programmes that restrict antiretrovirals to abstinent individuals should be re-examined. The lower rates of virological suppression associated with ongoing drug use nevertheless highlight the importance of comprehensive systems of care and addiction treatment for active drug users.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20710061     DOI: 10.3851/IMP1614

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  17 in total

1.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

2.  Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.

Authors:  Ryan McNeil; Thomas Kerr; Bill Coleman; Lisa Maher; M J Milloy; Will Small
Journal:  AIDS Behav       Date:  2017-02

3.  Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective.

Authors:  Elizabeth Y Lambert; Jacques L Normand; Nora D Volkow
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

4.  "Damaging what wasn't damaged already": psychological tension and antiretroviral adherence among HIV-infected methadone-maintained drug users.

Authors:  A W Batchelder; M Brisbane; A H Litwin; S Nahvi; K M Berg; J H Arnsten
Journal:  AIDS Care       Date:  2013-02-13

5.  Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.

Authors:  Aranka Anema; Thomas Kerr; M-J Milloy; Cindy Feng; Julio S G Montaner; Evan Wood
Journal:  AIDS Care       Date:  2013-09-09

6.  Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.

Authors:  Thomas Kerr; Brandon D L Marshall; M-J Milloy; Ruth Zhang; Silvia Guillemi; Julio S G Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2012-01-14       Impact factor: 4.492

7.  Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.

Authors:  M-J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Andrea Krusi; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

8.  Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users.

Authors:  M J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood
Journal:  J Infect Dis       Date:  2011-05-01       Impact factor: 5.226

9.  Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users.

Authors:  B Mann; M-J Milloy; T Kerr; R Zhang; J Montaner; E Wood
Journal:  HIV Med       Date:  2012-05-02       Impact factor: 3.180

10.  Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment.

Authors:  Brandon Aden; Allison Dunning; Bohdan Nosyk; Eve Wittenberg; Jeremy W Bray; Bruce R Schackman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.